FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as SixBusiness Wire • 03/28/24
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramBusiness Wire • 03/28/24
Nucleus RadioPharma Announces Appointment of Chris McDonald from Kite, a Gilead Company, to Board of DirectorsBusiness Wire • 03/27/24
Christi Shaw, Former CEO of Kite, a Gilead Company, Appointed to Cellares Advisory Board to Advance Cell Therapy ManufacturingBusiness Wire • 03/26/24
Gilead Sciences (GILD) Rises But Trails Market: What Investors Should KnowZacks Investment Research • 03/19/24
Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink GrantBusiness Wire • 03/18/24
Gilead Sciences, Inc. (GILD) Barclays 26th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 03/13/24
Gilead Sciences, Inc. (GILD) Leerink Partners Global Biopharma Conference (Transcript)Seeking Alpha • 03/13/24
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender OfferBusiness Wire • 03/11/24
Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and ComorbiditiesBusiness Wire • 03/06/24
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24Business Wire • 03/06/24
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell EngagersBusiness Wire • 03/06/24